// App-Quantinova.ai

e16131 : PRIME-HCC: Phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.

Researchers

Presenter

  • David James Pinato

Principal Investigators

  • Alessio Cortellini

  • Madhava Pai

  • Duncan Spalding

  • Thomas Talbot

  • Robert D. Goldin

  • Aneta Gupta

  • Tom Cole

  • Caroline Ward

  • Vincent S. Yip

  • Tony Singh Dhillon

  • Sarah Slater

  • Mikael Sodergren

  • Paul Tait

  • Nagy A. Habib

  • Robert Thomas

  • Rohini Sharma

Medical Centers

  • Department of Surgery & Cancer, Imperial College London, London, United Kingdom

  • Department of Biotechnological and Applied Clinical Sciences, University of LAquila, LAquila, Italy

  • Imperial College, St. Mary's Campus, London, United Kingdom

  • Imperial College, London, United Kingdom

  • Aintree University Hospital, Liverpool, United Kingdom

  • Royal Surrey County Hospital, Guildford, United Kingdom

  • Barts Health NHS Trust, London, United Kingdom

  • Imperial College, London, United Kingdom

Locations

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • N/A

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • I

Study Id's

  • NCT03682276

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved